CertiK joins the United Nations anti-fraud cooperation framework to help combat cross-border Web3-related crimes
Odaily reported that on March 20, CertiK, the world's largest Web3 security company, announced that it has submitted an anti-fraud commitment at the 2026 United Nations Global Fraud Summit. CertiK will support the global fight against cross-border Web3-related crimes through technical support, threat intelligence, and investigative collaboration.
The summit is jointly organized by the United Nations Office on Drugs and Crime (UNODC) and INTERPOL, with technology and financial giants such as Google and Lloyds Banking Group also submitting commitments.
According to the disclosed information, CertiK's commitment focuses on three main areas: First, leveraging its security platform to provide real-time threat intelligence and on-chain risk monitoring, enhancing the ability of regulatory and law enforcement agencies to identify and respond to abnormal activities; Second, forming expert teams to provide technical support and forensic assistance for major cross-border attack incidents; Third, regularly providing blockchain security policy and technical briefings to UNODC, INTERPOL, and other relevant institutions, promoting the coordinated development of regulatory frameworks and technical capabilities.
Relying on its independently developed Skynet security platform and the industry's largest proprietary Web3 security database, CertiK has provided security services to 5,000 clients worldwide, continuously monitoring on-chain risk dynamics. As the digital asset market gradually becomes institutionalized, the security system is evolving from a single technical service into a key infrastructure supporting compliant regulation and market trust.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - RBC expects gradual improvement in North American and European building materials stocks in the third quarter
October 9 - RBC expects the performance of most European building material products to gradually improve quarter-on-quarter in Q3, but notes that geopolitical uncertainties in the US will continue to drive up cost inflation and increase market volatility. RBC anticipates that sales in Europe will remain sluggish due to heatwaves and rising mortgage rates, while a weak US housing market and the lack of a significant hurricane season will prompt roofing material companies to enter a destocking cycle. The firm is more optimistic about Germany’s Heidelberg Group (HEIG.DE), upgrading its rating to “outperform,” and points out that the company has handled the challenging quarter caused by extreme weather far better than its peers. Due to severe cost headwinds such as rising diesel and natural gas prices, RBC downgraded the ratings of US and French construction companies Knife River (KNF.N) and Saint-Gobain (SGOB.PA) from “outperform” to “market perform.” (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them solely for the ease of the reader. Reuters assumes no liability for any damages or losses that may arise from the use of automated translation functions.)
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Crypto prices
More
